NCT03199339View on ClinicalTrials.gov

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

July 8, 2018

Study Completion Date

July 8, 2018

Conditions
TuberculosisTuberculosis, Pulmonary
Interventions
DRUG

TBA-7371

The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

DRUG

Placebo

The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors
lead

Global Alliance for TB Drug Development

OTHER

NCT03199339 - A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 | Biotech Hunter | Biotech Hunter